Prevention of Pegfilgrastim-Induced Bone Pain: A Phase III Double-Blind Placebo-Controlled Randomized Clinical Trial of the University of Rochester Cancer Center Clinical Community Oncology Program Research Base
Conclusion
Our phase III randomized placebo-controlled clinical trial demonstrated that naproxen at a dose of 500 mg twice per day is
effective in reducing the incidence and severity of pegfilgrastim-induced bone pain.
Footnotes
-
See accompanying editorial doi: 10.1200/JCO.2011.41.3146 and article doi: 10.1200/JCO.2011.39.2381;
- listen to the podcast by Dr Von Hoenn at www.jco.org/podcasts
